JPM
JPMorgan Chase & Co.
JPM has the edge over NEWT overall, supported by stronger fundamentals and stronger modeled upside.
NEWT
NewtekOne, Inc.
NEWT offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
JPM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
JPM's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like JPM.
NEWT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| N/A | |
| N/A |
NEWT's revenue and profitability are currently stable. Free cash flow and net leverage aren't meaningful measures for financial services companies like NEWT.
JPM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.7x | $231 | -33% |
| Fair | 12x | $287 | -16% |
| Current | 14x | $343 | — |
| Forward | 14x | $343 | — |
| Expensive | 15x | $361 | +5.2% |
Historical ranges are pointers, not guarantees.
JPM's PE is in its expensive range at 14.4x. If earnings grow as analysts expect, today's price would be 13.7x next year's earnings.
NEWT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 5.2x | $10.44 | — |
| Cheap | 5.5x | $10.25 | -1.8% |
| Current | 5.6x | $10.44 | — |
| Fair | 7.1x | $13.41 | +28% |
| Expensive | 10x | $19.07 | +83% |
Historical ranges are pointers, not guarantees.
NEWT has the edge over JPM in the historical PE scenario, which offers more potential upside but is not a forecast.
JPM Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Growth | |
| Improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for JPM, with profitability improving.
NEWT Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Stable | |
| Stable | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NEWT's profitability to weaken, with its earnings and revenue holding steady. However, they disagree widely on these estimates.
JPM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $24.99 | +4.8% |
| Q3 2026 | $23.85 | +18% |
| Q2 2026 | $23.35 | +20% |
| Q1 2026 | $20.89 | +2.5% |
| Q4 2025 | $20.02 | +1.4% |
| Q3 2025 | $20.20 | +12% |
| Q2 2025 | $19.50 | +8.7% |
| Q1 2025 | $20.38 | +23% |
| Q4 2024 | $19.75 | +22% |
JPM's earnings per share have climbed steadily: $23.85 over the past year, up 18% from the year before, and higher year over year for 15 quarters in a row.
NEWT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.02 | +7.3% |
| Q3 2026 | $1.88 | -16% |
| Q2 2026 | $2.21 | +9.4% |
| Q1 2026 | $2.26 | +17% |
| Q4 2025 | $2.18 | +11% |
| Q3 2025 | $2.24 | +32% |
| Q2 2025 | $2.02 | +24% |
| Q1 2025 | $1.93 | +32% |
| Q4 2024 | $1.96 | +27% |
NEWT earned $1.88 per share over the past year, down 16% from the year before.
JPM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $50.2B | +8.1% |
| Q2 2026 | $57.3B | +28% |
| Q1 2026 | $49.8B | +10% |
| Q4 2025 | $45.8B | +7.1% |
| Q3 2025 | $46.4B | +8.8% |
| Q2 2025 | $44.9B | -11% |
| Q1 2025 | $45.3B | +8.1% |
| Q4 2024 | $42.8B | +11% |
JPM's revenue has grown year over year for five quarters in a row: $50.2B last quarter, up 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 40% | -0.2 points |
| Q2 2026 | 48% | +7.3 points |
| Q1 2026 | 41% | +0.5 points |
| Q4 2025 | 37% | -3.2 points |
| Q3 2025 | 40% | +0.6 points |
| Q2 2025 | 41% | -6 points |
| Q1 2025 | 41% | -0.6 points |
| Q4 2024 | 41% | +11 points |
JPM's operating margin was 40% last quarter, about level with the same quarter a year ago.
NEWT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $71.8M | -4.2% |
| Q2 2026 | $75.1M | +7% |
| Q1 2026 | $71M | +7% |
| Q4 2025 | $73.3M | -2.7% |
| Q3 2025 | $74.9M | +19% |
| Q2 2025 | $70.2M | +15% |
| Q1 2025 | $66.3M | +14% |
| Q4 2024 | $75.4M | +42% |
NEWT's revenue has held roughly level: $72M last quarter, down 4.2% from the same quarter a year ago.
JPM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $33.2B | +$78.4B |
| Q2 2026 | -$25.3B | -186% |
| Q1 2026 | -$211.8B | +$40.1B |
| Q4 2025 | $119.7B | -19% |
| Q3 2025 | -$45.2B | +$28.9B |
| Q2 2025 | $29.5B | -23% |
| Q1 2025 | -$251.8B | -$97.7B |
| Q4 2024 | $147.8B | +145% |
JPM has the edge over NEWT on cash flow, with more consistent year-over-year improvement.
NEWT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$152.4M | +$14.9M |
| Q2 2026 | -$163.3M | +$36.6M |
| Q1 2026 | -$257.5M | -$196.8M |
| Q4 2025 | -$151.4M | -$59.8M |
| Q3 2025 | -$167.3M | -$141.4M |
| Q2 2025 | -$199.9M | -7108% |
| Q1 2025 | -$60.7M | -$22M |
| Q4 2024 | -$91.7M | -$39M |
NEWT's free cash flow was −$725M over the past year, against −$520M the year before. Free cash flow isn't a meaningful measure for financial services companies like NEWT.
JPM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -11.2M shares |
| 1 year | -3.1% | -84.6M shares |
| 3 years | -8.5% | -249M shares |
| 5 years | -11% | -322M shares |
| Available history | -17% | -547M shares |
JPM has the edge over NEWT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1.1B |
| Q2 2026 | $6.8B |
| Q1 2026 | $8.3B |
| Q4 2025 | $8.3B |
| Q3 2025 | $8.3B |
| Q2 2025 | $7.5B |
| Q1 2025 | $7.5B |
| Q4 2024 | $4.3B |
JPM spent $24.5B buying back its own shares over the past year, down 11% from the year before.
NEWT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +51K shares |
| 1 year | +10% | +2.7M shares |
| 3 years | +16% | +4M shares |
NEWT has 29M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $167,000 |
| Q3 2025 | — |
JPM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.5x | Very low |
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | 0.5x | Very low |
| Q3 2025 | 0.6x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.4x | Very low |
JPM's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like JPM.
NEWT Net Leverage
JPM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.8 | Neutral |
| Stochastic | 31.5 | Neutral |
JPM's weekly RSI is 55 (neutral) and its Stochastic is 31 (neutral).
NEWT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 35.9 | Neutral |
| Stochastic | 2.7 | Oversold |
NEWT's weekly RSI is 36 (neutral) and its Stochastic is 3 (oversold).
JPM PE vs Financial Services Sector
| Metric | JPM | Sector median | Relative |
|---|---|---|---|
| PE | 14x | 13x | 10% above |
| PE % | 76 | 63 | 13 pts above |
JPM is trading at 14x earnings, a 10% premium to the Financial Services sector's median of 13x.
NEWT PE vs Financial Services Sector
| Metric | NEWT | Sector median | Relative |
|---|---|---|---|
| PE | 5.6x | 13x | 57% below |
| PE % | 19 | 63 | 44 pts below |
NEWT has the edge over JPM on valuation relative to its sector.
JPM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $336.8 | 1.8% above |
| 20 week MA | $345.3 | 0.7% below |
| 50 week MA | $323.2 | 6.1% above |
| 100 week MA | $298.9 | 15% above |
| 200 week MA | $236.6 | 45% above |
JPM has the edge over NEWT on trend strength, trading above more of its moving averages.
NEWT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.0 | 4.7% below |
| 20 week MA | $12.4 | 16% below |
| 50 week MA | $12.6 | 17% below |
| 100 week MA | $12.1 | 14% below |
| 200 week MA | $13.0 | 19% below |
NEWT is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
JPM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $139.1 | $124.5 | -11% |
| 2021 | $124.5 | $157.3 | +26% |
| 2022 | $157.3 | $131.3 | -17% |
| 2023 | $131.3 | $170.1 | +30% |
| 2024 | $170.1 | $241.2 | +42% |
| 2025 | $241.2 | $327.9 | +36% |
| 2026 YTD | $327.9 | $342.8 | +4.5% |
JPM has the edge over NEWT on returns for 2026, with the stronger performance.
NEWT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $22.7 | $18.2 | -20% |
| 2021 | $18.2 | $27.9 | +54% |
| 2022 | $27.9 | $16.7 | -40% |
| 2023 | $16.7 | $13.8 | -17% |
| 2024 | $13.8 | $13.0 | -5.7% |
| 2025 | $13.0 | $11.5 | -12% |
| 2026 YTD | $11.5 | $10.4 | -9.1% |
NEWT has finished four years in a row lower, and it's down 9.1% so far in 2026.